CD276 and glioblastoma: Given that elevated levels of B7-H3 can potentiate tumor cell response to targeted B7-H3 therapy, a promising strategy for treating GBM could involve combining AURKA inhibitors (such as alisertib) with monoclonal antibodies targeting B7-H3 (27, 28).